Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

Tobramycin Inhaled Powder (TOBI® Podhaler™)

To Patients

To Patients

Therapeutic Approach


The TOBI® Podhaler™ is the powder form of the inhaled antibiotic tobramycin and is used to treat people with CF who have Pseudomonas aeruginosa. It is taken with an inhaler, making it a convenient alternative to TOBI®, which must be taken using a nebulizer.


The TOBI Podhaler received FDA approval in March 2013 for people with CF.

In Australia, the TOBI Podhaler is awaiting PBAC reommendation for reimbursement.


The program is sponsored in the US by Novartis Pharmaceuticals and supported by Cystic Fibrosis Foundation Therapeutics (CFFT). The trial was conducted within CFFT's Therapeutics Development Network.

Contact us about Tobramycin Inhaled Powder (TOBI® Podhaler™) >